Several studies have supported the use of Janus kinase (JAK) inhibitors for repigmentation in patients with vitiligo. 1-3 Two phase 3 randomized clinical trials were carried out in 674 patients to investigate the use of ruxolitinib a JAK 1 and 2 for repigmentation of vitiligo lesions. 4 Here’s a summary of the “topical ruxolitinib evaluation in vitiligo studies 1 and 2” from The New England Journal of Medicine, 2022 . Rationale: What was the need for the study?
Small-scale studies report repigmentation in vitiligo patients with the use of JAK inhibitors. Given the lack of approved treatments for vitiligo lesions in the US and Europe, these phase 3 trials provide further evidence. Design: How was the study conducted? Patients were randomly assigned in a 2:1 ratio to apply 1.5% ruxolitinib or matching vehicle cream twice daily to all depigmented vitiligo lesions on the face and body for…
